AIM: To explore the efficacy and safety of hyperbaric oxygen therapy combined with jolethin in treating central serous chorioretinopathy.

METHODS: Totally, 100 cases(118 eyes)of central serous chorioretinopathy hospitalized in our hospital from July 2008 to July 2012 were divided into control group and observation group according to random lot method. The control group only received hyperbaric oxygen treatment, and the observation group was given joint treatment with hyperbaric oxygen and iodized lecithin. The clinical outcome, healing condition at different times after treatment, visual acuity before and after treatment, the recurrence rate and adverse reaction were compared.

RESULTS:(1)The control group consisted of 60 eyes and 43 eyes showed therapeutic efficacy, and the total effective rate was 71.7%; the observation group consisted of 58 eyes and 51 eyes showed therapeutic efficacy, and the total effective rate was 87.9%, and there was a statistical difference between the two groups(P<0.05);(2)There was a statistical difference in number of recovered eyes 2, 4 weeks and 3 months after treatment(P<0.05, P<0.01);(3)There was a statistical difference in visual acuity comparison between the two groups before and after treatment(P<0.05, P<0.01), and visual acuity after treatment in the observation group was significantly better than that in the control group(P<0.05);(4)After 1-year follow-up, in the control group, the number of eyes with recurrence was 6, and the recurrence rate was 10.0%; in the observation group, the recurrence rate was 0, and the difference was of great statistical significance(P<0.01).(5)There was no significant difference in adverse reaction during the treatment(P> 0.05).

CONCLUSION:Hyperbaric oxygen therapy combined with jolethin in treating central serous chorioretinopathy shows significant effect and high safety. It is worth to be promoted and applied in the clinical treatment of central serous chorioretinopathyd.